Mike Hindle is the Peter R. Byron Distinguished Professor in the Department of Pharmaceutics at Virginia Commonwealth University. He has a Pharmacy degree and a Ph.D. in Pharmaceutical Technology, both from the University of Bradford, UK.
He has published over 140 papers, one book chapter and served as co-editor of five books. He has received funding from National Institutes of Health (NIH), the Food and Drug Administration and the Bill and Melinda Gates Foundation together with the pharmaceutical industry. He serves on the editorial board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery and the AAPS PharmSciTech Journal. He is a member of the NIH Drug and Biologic Therapeutic Delivery study section and has served on over 30 NIH review panels.
He holds 10 U.S. patents and 5 E.U. patents and was inducted as a Fellow of National Academy of Inventors in 2023. Hindle is co-inventor of technologies that seek to significantly improve pharmaceutical aerosol delivery to the lungs and his research is particularly focused on challenging patient populations such as infants, in which he combines in silico computational fluid dynamics (CFD) with in vitro characterization studies. His group is currently developing a dry powder lung surfactant formulation to treat premature infants and adults with respiratory distress syndrome.
Our pharmaceutical aerosol development laboratories are located on the MCV campus of Virginia Commonwealth University. This interdisciplinary group works in collaboration with Dr Worth Longest (Department of Mechanical Engineering) to combine computational fluid dynamics (CFD) and design engineering to produce novel pharmaceutical aerosol drug delivery systems. Current projects are developing high efficiency methods of delivering dry powder aerosol surfactant to critically ill babies and adults with respiratory distress syndrome.
Our groups have also focused on the development of innovative in silico and in vitro methods to assess the pulmonary deposition from commercial inhalers using realistic oropharyngeal models.
We have received funding from the National Institutes of Health, the Food and Drug Administration, the Bill and Melinda Gates Foundation and the Pharmaceutical Industry.
Some of our currently funded projects are:
Development of Synthetic Lung Surfactant Formulations and Delivery Devices for Treating Infants with RDS in Low Resource Environments (Bill and Melinda Gates Foundation)
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support (NIH/NHLBI)
B.Pharm, Bradford, UK
Ph.D. Bradford, UK
Postgraduate Training
Post Doctoral Fellow (Virginia Commonwealth University)
